Abstract A27: Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
Authors: Michael E. Feigin, Tyler Garvin, Peter Bailey, Nicola Waddell, David K. Chang, Shimin Shuai, Steven Gallinger, John D. McPherson, Sean M. Grimmond, Ekta Khurana, Lincoln D. Stein, Andrew V. Biankin, Michael C. Schatz, David A. Tuveson
Journal: Cancer Research (2016)

Abstract Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with a 5-year survival rate of 6%, due in part to therapy resistance and late stage at diagnosis. A detailed understanding of the molecular alterations underlying PDA is required to uncover mechanisms of tumorigenesis and enable development of more effective therapies. As such, large-scale exome sequencing efforts have revealed genes (KRAS, TP53, CDKN2A, SMAD4) and pathways (Wnt/Notch, TGFβ, axon guidance, cell adhesion) important for PDA progression. However, the exome comprises less than 2% of the human genome. Whole-genome sequencing analyses have uncovered a somatic mutation rate of 1 mutation per megabase in PDA. Therefore, PDA tumors carry thousands of somatic mutations per genome, mostly located in noncoding regions, the vast majority of which are completely uncharacterized. While the contributions of coding mutations to tumorigenesis are relatively well known, few studies have detailed alterations in noncoding DNA. Here we describe a new computational pipeline, GECCO (Genomic Enrichment Computational Clustering Operation) to analyze somatic noncoding alterations in 308 pancreatic ductal adenocarcinomas (PDA) and systematically identify commonly mutated putative regulatory regions. We find that recurrent somatic noncoding regulatory mutations are present in PDA but uncommon near canonical PDA genes. Instead, using GECCO we find that the regulatory mutations are enriched in known PDA pathways, including axon guidance and cell adhesion, and novel processes including transcriptional regulation and homeobox genes. We identify mutations in specific protein binding sites that correlate with significant differential expression of proximal genes. Furthermore, to explore the effects of these candidate mutations on gene expression, we developed an expression modulation score that quantifies the strength of gene regulation imposed by each class of regulatory elements. Surprisingly, we find that the strongest regulatory elements are also the most frequently mutated, suggesting a selective advantage for mutations in these regions. Our analysis provides a detailed single-cancer view of noncoding alterations in tumorigenesis, identifies recurrent regulatory mutations as new candidates for diagnostic and prognostic markers, and suggests novel mechanisms for tumor genome evolution. Citation Format: Michael E. Feigin, Tyler Garvin, Peter Bailey, Nicola Waddell, David K. Chang, Shimin Shuai, Steven Gallinger, John D. McPherson, Sean M. Grimmond, Ekta Khurana, Lincoln D. Stein, Andrew V. Biankin, Michael C. Schatz, David A. Tuveson.{Authors}. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr A27.